Menu
← Oncology Approval Tracker
FDA DECISION ·
Polivy + R-CHP
polatuzumab vedotin-piiq + rituximab product + cyclophosphamide + doxorubicin + prednisone · Genentech
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults with previously untreated DLBCL not otherwise specified or high-grade B-cell lymphoma and an International Prognostic Index score of at least 2.
LAMPGEN ANALYSIS
Why it matters
The expansion introduced polatuzumab into a first-line regimen for higher-risk disease.
What research teams should watch
Capture the IPI score and reconcile the exact regimen before drug preparation and monitoring.
Related study operations checklist
See the staffing responsibilities, timing, and handoff questions for this study setting.
Frontline DLBCLPRIMARY RECORDS